Benzinga | Apr 5, 2021 08:03AM EDT

Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study

* Bio-Path Holdings Inc (NASDAQ: BPTH) has completed the safety run-in of Stage 2 of the Phase 2 study evaluating prexigebersen to treat acute myeloid leukemia (AML) in combination with frontline therapies, decitabine and venetoclax.

* The safety run-in comprised six evaluable patients.

* In the preliminary safety data review, five patients responded to treatment, including four achieving complete response (CR) and one complete response with incomplete hematologic recovery (CRi).

* CR rates to combination treatment with decitabine and venetoclax for relapsed/refractory AML patients is 42-52% and 0-39% for relapsed/refractory secondary AML patients.

* Response rates to frontline treatment decitabine and venetoclax for newly diagnosed AML patients are 62-71%.

* Interim data showed the treatment was well-tolerated, and no dose-limiting toxicities were observed.

* Three patients remained on treatment for more than one cycle.

* The Phase 2 clinical trial continues with 21 patients currently enrolled across all three cohorts.

* Price Action: BPTH shares are up 19.5% at $8.4 in the premarket trading on the last check Monday.